Fang Z, Ding YX, Li F. Exosomes: Promising biomarkers and targets for cancer. World J Gastrointest Oncol 2022; 14(8): 1594-1596 [PMID: 36160736 DOI: 10.4251/wjgo.v14.i8.1594]
Corresponding Author of This Article
Zhen Fang, PhD, Academic Research, Surgeon, Department of General Surgery, Xuanwu Hospital of Capital Medical University, No. 45 Changchun Street, Xicheng District, Beijing 100053, China. ifang123@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Aug 15, 2022; 14(8): 1594-1596 Published online Aug 15, 2022. doi: 10.4251/wjgo.v14.i8.1594
Exosomes: Promising biomarkers and targets for cancer
Zhen Fang, Yi-Xuan Ding, Fei Li
Zhen Fang, Yi-Xuan Ding, Fei Li, Department of General Surgery, Xuanwu Hospital of Capital Medical University, Beijing 100053, China
Author contributions: Fang Z and Ding YX wrote the manuscript; Li F designed the study; and All authors have read and approve the final manuscript.
Conflict-of-interest statement: All authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhen Fang, PhD, Academic Research, Surgeon, Department of General Surgery, Xuanwu Hospital of Capital Medical University, No. 45 Changchun Street, Xicheng District, Beijing 100053, China. ifang123@163.com
Received: February 17, 2022 Peer-review started: February 17, 2022 First decision: April 17, 2022 Revised: April 25, 2022 Accepted: July 19, 2022 Article in press: July 19, 2022 Published online: August 15, 2022 Processing time: 174 Days and 4.6 Hours
Abstract
The review article entitled "Exosomes as potential diagnosis and treatment for liver cancer " recently published in World Journal of Gastrointestinal Oncology 2022; 14: 334-347 concluded that exosomes can be used as effective biomarkers or therapeutic biotargets in liver cancer. Exosomes are a hot spot in the field of tumor diagnosis and treatment research. We had also previously published a review on exosomes and tumors. In this letter to the editor, we summarize the clinical application prospects and current challenges of exosomes.
Core Tip: Exosomes have been shown to be major transmitters of cell-to-cell communication. Several advantageous features make exosomes effective therapeutic targets for cancer and ideal vehicles for drug delivery. This letter highlights the opportunities and challenges for clinical study and application of exosomes.
